Incyte pulls away 'damaged goods' baricitinib to focus on internal pipeline
Jakafi-maker Incyte has effectively made Olumiant (baricitinib) — the tarnished JAK inhibitor dogged by safety concerns that barely crossed the FDA finish line with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
